IA
RUBY

IndexIQ Advisors’s Rubius Therapeutics, Inc RUBY Stock Holding History

IndexIQ Advisors’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$439K Buy
+79,691
New +$506K 0.02% 432

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return

IndexIQ Advisors's RUBY Position: Q1 2022 in Review

IndexIQ Advisors opened a new position in Rubius Therapeutics, Inc (RUBY) in Q1 2022: 79,691 shares worth $439K. The stake represents 0.02% of the portfolio and ranks #432 among its holdings.

117 funds tracked by Wall St. Rank hold RUBY as of Q1 2022.

  • IndexIQ Advisors held 79,691 shares of Rubius Therapeutics, Inc worth $439K as of Q1 2022.
  • Rubius Therapeutics, Inc was a new IndexIQ Advisors position in Q1 2022.
  • Rubius Therapeutics, Inc made up 0.02% of IndexIQ Advisors's portfolio in Q1 2022, its #432 holding.
  • 117 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.